104 related articles for article (PubMed ID: 38714355)
1. MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma.
Ioannou M; Lalwani K; Ayanlaja AA; Chinnasamy V; Pratilas CA; Schreck KC
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38714355
[TBL] [Abstract][Full Text] [Related]
2. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
[TBL] [Abstract][Full Text] [Related]
5. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
6. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
See WL; Tan IL; Mukherjee J; Nicolaides T; Pieper RO
Cancer Res; 2012 Jul; 72(13):3350-9. PubMed ID: 22573716
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.
Harder A
Biomark Res; 2021 Apr; 9(1):26. PubMed ID: 33863389
[TBL] [Abstract][Full Text] [Related]
9. An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS; Blakeley J; Rodriguez FJ
Acta Neuropathol; 2020 Apr; 139(4):625-641. PubMed ID: 30963251
[TBL] [Abstract][Full Text] [Related]
10. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
[TBL] [Abstract][Full Text] [Related]
11. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
12. Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.
Dougherty J; Harvey K; Liou A; Labella K; Moran D; Brosius S; De Raedt T
PLoS One; 2023; 18(2):e0277305. PubMed ID: 36730269
[TBL] [Abstract][Full Text] [Related]
13. Global microRNA profiling identified miR-10b-5p as a regulator of neurofibromatosis 1 (NF1)-glioma migration.
Nix JS; Yuan M; Imada EL; Ames H; Marchionni L; Gutmann DH; Rodriguez FJ
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):96-107. PubMed ID: 32603552
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
15. Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma.
Schreck KC; Allen AN; Wang J; Pratilas CA
Neurooncol Adv; 2020; 2(1):vdaa138. PubMed ID: 33235998
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.
Helfferich J; Nijmeijer R; Brouwer OF; Boon M; Fock A; Hoving EW; Meijer L; den Dunnen WF; de Bont ES
Crit Rev Oncol Hematol; 2016 Aug; 104():30-41. PubMed ID: 27263935
[TBL] [Abstract][Full Text] [Related]
18. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
19. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
20. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]